| CAS NO: | 100299-08-9 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| Molecular Weight (MW) | 266.3 |
|---|---|
| Formula | C10H7N6O.K |
| CAS No. | 100299-08-9 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: <1 mg/mL |
| Water: 53 mg/mL (199.0 mM) | |
| Ethanol: <1 mg/mL | |
| Other info | Chemical Name: potassium 5-(9-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)tetrazol-1-ide InChi Key: NMMVKSMGBDRONO-UHFFFAOYSA-N InChi Code: InChI=1S/C10H7N6O.K/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8;/h2-5H,1H3;/q-1;+1 SMILES Code: O=C1C(C2=NN=NN2[K])=CN=C3N1C=CC=C3C |
| Synonyms | TWT-8152; BMY 26517; TWT 8152; BMY 26517; TWT8152; BMY 26517; Pemirolast; Pemirolast potassium. trade name: Alegysal and Alamast. |
| In Vitro | In vitro activity: Pemirolast potassium (BMY 26517) is a new oral, nonbronchodilator antiallergy medication that is being evaluated for the therapy of asthma. Pemirolast potassium (BMY 26517) inhibits chemical mediator release from tissue mast cells and is also shown to inhibit the release of peptides including substance P, neurokinin (NK) A, and calcitonin gene-related peptide (CGRP) from sensory nerves. Pemirolast potassium is used for the treatment of allergic conjunctivitis and prophylaxis for pulmonary hypersensitivity reactions to drugs such as paclitaxel. |
|---|---|
| In Vivo | Pemirolast potassium (BMY 26517) reduces kaolin intake by inhibition of substance P release in rats. Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. |
| Animal model | Rats |
| Formulation & Dosage | |
| References | Ann Allergy. 1992 Jun;68(6):488-91; Eur J Pharmacol. 2011 Jul 1;661(1-3):57-62. |
m.cnreagent.com